Literature DB >> 18654570

Economic issues with follow-on protein products.

Michael Lanthier1, Rachel Behrman, Clark Nardinelli.   

Abstract

The economic effects of the possible introduction of 'follow-on' protein products have been the subject of recent debate. Here, we aim to explore the economic issues surrounding this debate using three measures: total sales, product complexity and patent expiry. Our analysis shows that the sales of therapeutic protein products are concentrated in a relatively small number of branded products, which may be the most attractive targets for follow-on development. For the years 2013-2015, we estimate that products representing US$20 billion in annual sales--approximately half of all sales in 2006--can be expected to lose patent protection.

Mesh:

Substances:

Year:  2008        PMID: 18654570     DOI: 10.1038/nrd2636

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  9 in total

Review 1.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

2.  Medicinal chemistry for 2020.

Authors:  Seetharama D Satyanarayanajois; Ronald A Hill
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

3.  Gearing up for follow-on biologics.

Authors:  Bethan Hughes
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

4.  European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK.

Authors:  Janice M Reichert; Alain Beck; Harish Iyer
Journal:  MAbs       Date:  2009-09-25       Impact factor: 5.857

5.  Biosimilars 2.0: guiding principles for a global "patients first" standard.

Authors:  Joseph Miletich; Geoffrey Eich; Gustavo Grampp; Barbara Mounho
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

6.  5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.

Authors:  Alain Beck; Janice M Reichert; Thierry Wurch
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

Review 7.  Biosimilar agents in oncology/haematology: from approval to practice.

Authors:  Dietger Niederwieser; Stephan Schmitz
Journal:  Eur J Haematol       Date:  2011-01-25       Impact factor: 2.997

8.  Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs.

Authors:  Alex Colbert; Amber Umble-Romero; Samantha Prokop; Vincent Fung-Sing Chow; Teresa Wong; Danielle DeSimone; Lei Zhou; Susan Pederson
Journal:  MAbs       Date:  2014       Impact factor: 5.857

9.  Advances in Mammalian cell line development technologies for recombinant protein production.

Authors:  Tingfeng Lai; Yuansheng Yang; Say Kong Ng
Journal:  Pharmaceuticals (Basel)       Date:  2013-04-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.